The data of IOD indicated that pancreatic tumor tissue in QYHJ treatment group had less immunohistochemical staining of Hes-1 expression and Hey-1 expression as compared to control group (P < 0.001), while no statistical difference was found in gemcitabine treatment group (P > 0.05). This evidence concerns the gene HES1 and pancreatic neoplasm.